News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Yakup Ergün: Ivonescimab (PD-1 × VEGF) and Tarlatamab (DLL3 × CD3) are My Favorite Drugs For Lung Cancer – Even Better Ones Are Yet to Come
Yakup Ergün/obdh.com.tr
Jun 19, 2025, 11:53

Yakup Ergün: Ivonescimab (PD-1 × VEGF) and Tarlatamab (DLL3 × CD3) are My Favorite Drugs For Lung Cancer – Even Better Ones Are Yet to Come

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X:

“The next generation of immunotherapies for lung cancers
Although there are many drugs currently in development, my current favorites are ivonescimab (PD-1 × VEGF) and tarlatamab (DLL3 × CD3).
Even better ones are yet to come.”
ivonescimab

Title: The next generation of immunotherapies for lung cancers

Authors: Shen Zhao, Hongyun Zhao, Weiwei Yang, Li Zhang

Read Full Article.

Yakup Ergün: Ivonescimab (PD-1 × VEGF) and Tarlatamab (DLL3 × CD3) are My Favorite Drugs For Lung Cancer - Even Better Ones Are Yet to Come

More posts featuring Yakup Ergün.

cancer Hongyun Zhao Li Zhang lung cancers OncoDaily Oncology Shen Zhao Weiwei Yang
Special Coverage
Blog
Jun 19, 2025, 16:12
World Kidney Cancer Day 2025: Uniting for Progress in the Fight Against Renal Cell Carcinoma
Blog
Jun 19, 2025, 16:01
IARC Marks World Kidney Cancer Day with New Video and Project Highlights
Science
Jun 19, 2025, 15:50
Alexey Kulikov Shared An Article on Cancer Vaccines and The Future of Immunotherapy
Opinion
Jun 19, 2025, 15:47
Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan
Blog
Jun 19, 2025, 15:36
Amol Akhade: KEYNOTE-689 - A Turning Point in Resectable HNSCC - Or a Cautious Step Forward?
Drugs
Jun 19, 2025, 15:30
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma
Blog
Jun 19, 2025, 15:15
Antonio Jimenez Jimenez Shared Findings from the Multicenter ACCESS trial, Supported by CIBMTR and NMDP
Blog
Jun 19, 2025, 14:35
Peter Pisters: Pleased to Join the 1st Institute for Cell Therapy Discovery and Innovation's External Advisory Board meeting
Insight
Jun 19, 2025, 14:22
Ron Alfa: Noetik and Agenus Announced an Exciting Collaboration to Deploy Foundation Models to Predict Immunotherapy Response
Blog
Jun 19, 2025, 13:42
Raffaele Colombo: Preclinical development of DB-1419 published on Clinical Cancer Research AACR
Blog
Jun 19, 2025, 13:21
Mohamed Kharfan-Dabaja: Happy to Share Our Clinical Practice Recommendations in CLL on behalf of ASTCT
Oncolibrary
Jun 19, 2025, 13:13
New Paper Alert: KEYNOTE-689. Neoadjuvant and Adjuvant Pembrolizumab Improves Survival in Locally Advanced HNC